Table of Content

1 Metastatic Ovarian Cancer Drug Market Overview
1.1 Metastatic Ovarian Cancer Drug Product Scope
1.2 Metastatic Ovarian Cancer Drug Segment by Type
1.2.1 Global Metastatic Ovarian Cancer Drug Sales by Type (2016 & 2021 & 2027)
1.2.2 E-7449
1.2.3 Crizotinib
1.2.4 CMB-305
1.2.5 G-305
1.2.6 LV-305
1.2.7 Others
1.3 Metastatic Ovarian Cancer Drug Segment by Application
1.3.1 Global Metastatic Ovarian Cancer Drug Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Metastatic Ovarian Cancer Drug Market Estimates and Forecasts (2016-2027)
1.4.1 Global Metastatic Ovarian Cancer Drug Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Metastatic Ovarian Cancer Drug Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Metastatic Ovarian Cancer Drug Price Trends (2016-2027)

2 Metastatic Ovarian Cancer Drug Estimates and Forecasts by Region
2.1 Global Metastatic Ovarian Cancer Drug Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Metastatic Ovarian Cancer Drug Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Metastatic Ovarian Cancer Drug Sales Market Share by Region (2016-2021)
2.2.2 Global Metastatic Ovarian Cancer Drug Revenue Market Share by Region (2016-2021)
2.3 Global Metastatic Ovarian Cancer Drug Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Metastatic Ovarian Cancer Drug Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Metastatic Ovarian Cancer Drug Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Metastatic Ovarian Cancer Drug Estimates and Projections (2016-2027)
2.4.2 Europe Metastatic Ovarian Cancer Drug Estimates and Projections (2016-2027)
2.4.3 China Metastatic Ovarian Cancer Drug Estimates and Projections (2016-2027)
2.4.4 Japan Metastatic Ovarian Cancer Drug Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Metastatic Ovarian Cancer Drug Estimates and Projections (2016-2027)
2.4.6 India Metastatic Ovarian Cancer Drug Estimates and Projections (2016-2027)

3 Global Metastatic Ovarian Cancer Drug Competition Landscape by Players
3.1 Global Top Metastatic Ovarian Cancer Drug Players by Sales (2016-2021)
3.2 Global Top Metastatic Ovarian Cancer Drug Players by Revenue (2016-2021)
3.3 Global Metastatic Ovarian Cancer Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Metastatic Ovarian Cancer Drug as of 2020)
3.4 Global Metastatic Ovarian Cancer Drug Average Price by Company (2016-2021)
3.5 Manufacturers Metastatic Ovarian Cancer Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global Metastatic Ovarian Cancer Drug Market Size by Type
4.1 Global Metastatic Ovarian Cancer Drug Historic Market Review by Type (2016-2021)
4.1.1 Global Metastatic Ovarian Cancer Drug Sales Market Share by Type (2016-2021)
4.1.2 Global Metastatic Ovarian Cancer Drug Revenue Market Share by Type (2016-2021)
4.1.3 Global Metastatic Ovarian Cancer Drug Price by Type (2016-2021)
4.2 Global Metastatic Ovarian Cancer Drug Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Metastatic Ovarian Cancer Drug Sales Forecast by Type (2022-2027)
4.2.2 Global Metastatic Ovarian Cancer Drug Revenue Forecast by Type (2022-2027)
4.2.3 Global Metastatic Ovarian Cancer Drug Price Forecast by Type (2022-2027)

5 Global Metastatic Ovarian Cancer Drug Market Size by Application
5.1 Global Metastatic Ovarian Cancer Drug Historic Market Review by Application (2016-2021)
5.1.1 Global Metastatic Ovarian Cancer Drug Sales Market Share by Application (2016-2021)
5.1.2 Global Metastatic Ovarian Cancer Drug Revenue Market Share by Application (2016-2021)
5.1.3 Global Metastatic Ovarian Cancer Drug Price by Application (2016-2021)
5.2 Global Metastatic Ovarian Cancer Drug Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Metastatic Ovarian Cancer Drug Sales Forecast by Application (2022-2027)
5.2.2 Global Metastatic Ovarian Cancer Drug Revenue Forecast by Application (2022-2027)
5.2.3 Global Metastatic Ovarian Cancer Drug Price Forecast by Application (2022-2027)

6 North America Metastatic Ovarian Cancer Drug Market Facts & Figures
6.1 North America Metastatic Ovarian Cancer Drug Sales by Company
6.1.1 North America Metastatic Ovarian Cancer Drug Sales by Company (2016-2021)
6.1.2 North America Metastatic Ovarian Cancer Drug Revenue by Company (2016-2021)
6.2 North America Metastatic Ovarian Cancer Drug Sales Breakdown by Type
6.2.1 North America Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2016-2021)
6.2.2 North America Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2022-2027)
6.3 North America Metastatic Ovarian Cancer Drug Sales Breakdown by Application
6.3.1 North America Metastatic Ovarian Cancer Drug Sales Breakdown by Application (2016-2021)
6.3.2 North America Metastatic Ovarian Cancer Drug Sales Breakdown by Application (2022-2027)

7 Europe Metastatic Ovarian Cancer Drug Market Facts & Figures
7.1 Europe Metastatic Ovarian Cancer Drug Sales by Company
7.1.1 Europe Metastatic Ovarian Cancer Drug Sales by Company (2016-2021)
7.1.2 Europe Metastatic Ovarian Cancer Drug Revenue by Company (2016-2021)
7.2 Europe Metastatic Ovarian Cancer Drug Sales Breakdown by Type
7.2.1 Europe Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2016-2021)
7.2.2 Europe Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2022-2027)
7.3 Europe Metastatic Ovarian Cancer Drug Sales Breakdown by Application
7.3.1 Europe 131 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 131 Sales Breakdown by Application (2022-2027)

8 China Metastatic Ovarian Cancer Drug Market Facts & Figures
8.1 China Metastatic Ovarian Cancer Drug Sales by Company
8.1.1 China Metastatic Ovarian Cancer Drug Sales by Company (2016-2021)
8.1.2 China Metastatic Ovarian Cancer Drug Revenue by Company (2016-2021)
8.2 China Metastatic Ovarian Cancer Drug Sales Breakdown by Type
8.2.1 China Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2016-2021)
8.2.2 China Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2022-2027)
8.3 China Metastatic Ovarian Cancer Drug Sales Breakdown by Application
8.3.1 China 154 Sales Breakdown by Application (2016-2021)
8.3.2 China 154 Sales Breakdown by Application (2022-2027)

9 Japan Metastatic Ovarian Cancer Drug Market Facts & Figures
9.1 Japan Metastatic Ovarian Cancer Drug Sales by Company
9.1.1 Japan Metastatic Ovarian Cancer Drug Sales by Company (2016-2021)
9.1.2 Japan Metastatic Ovarian Cancer Drug Revenue by Company (2016-2021)
9.2 Japan Metastatic Ovarian Cancer Drug Sales Breakdown by Type
9.2.1 Japan Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2016-2021)
9.2.2 Japan Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2022-2027)
9.3 Japan Metastatic Ovarian Cancer Drug Sales Breakdown by Application
9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Metastatic Ovarian Cancer Drug Market Facts & Figures
10.1 Southeast Asia Metastatic Ovarian Cancer Drug Sales by Company
10.1.1 Southeast Asia Metastatic Ovarian Cancer Drug Sales by Company (2016-2021)
10.1.2 Southeast Asia Metastatic Ovarian Cancer Drug Revenue by Company (2016-2021)
10.2 Southeast Asia Metastatic Ovarian Cancer Drug Sales Breakdown by Type
10.2.1 Southeast Asia Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Metastatic Ovarian Cancer Drug Sales Breakdown by Application
10.3.1 Southeast Asia K Pcs Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Pcs Sales Breakdown by Application (2022-2027)

11 India Metastatic Ovarian Cancer Drug Market Facts & Figures
11.1 India Metastatic Ovarian Cancer Drug Sales by Company
11.1.1 India Metastatic Ovarian Cancer Drug Sales by Company (2016-2021)
11.1.2 India Metastatic Ovarian Cancer Drug Revenue by Company (2016-2021)
11.2 India Metastatic Ovarian Cancer Drug Sales Breakdown by Type
11.2.1 India Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2016-2021)
11.2.2 India Metastatic Ovarian Cancer Drug Sales Breakdown by Type (2022-2027)
11.3 India Metastatic Ovarian Cancer Drug Sales Breakdown by Application
11.3.1 India Metastatic Ovarian Cancer Drug Sales Breakdown by Application (2016-2021)
11.3.2 India Metastatic Ovarian Cancer Drug Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Metastatic Ovarian Cancer Drug Business
12.1 Adgero Biopharmaceuticals Inc
12.1.1 Adgero Biopharmaceuticals Inc Corporation Information
12.1.2 Adgero Biopharmaceuticals Inc Business Overview
12.1.3 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Products Offered
12.1.5 Adgero Biopharmaceuticals Inc Recent Development
12.2 Cellceutix Corporation
12.2.1 Cellceutix Corporation Corporation Information
12.2.2 Cellceutix Corporation Business Overview
12.2.3 Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Cellceutix Corporation Metastatic Ovarian Cancer Drug Products Offered
12.2.5 Cellceutix Corporation Recent Development
12.3 Eisai Co., Ltd.
12.3.1 Eisai Co., Ltd. Corporation Information
12.3.2 Eisai Co., Ltd. Business Overview
12.3.3 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Products Offered
12.3.5 Eisai Co., Ltd. Recent Development
12.4 F. Hoffmann-La Roche Ltd.
12.4.1 F. Hoffmann-La Roche Ltd. Corporation Information
12.4.2 F. Hoffmann-La Roche Ltd. Business Overview
12.4.3 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2016-2021)
12.4.4 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Products Offered
12.4.5 F. Hoffmann-La Roche Ltd. Recent Development
12.5 Immune Design Corp.
12.5.1 Immune Design Corp. Corporation Information
12.5.2 Immune Design Corp. Business Overview
12.5.3 Immune Design Corp. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Immune Design Corp. Metastatic Ovarian Cancer Drug Products Offered
12.5.5 Immune Design Corp. Recent Development
12.6 Millennium Pharmaceuticals Inc
12.6.1 Millennium Pharmaceuticals Inc Corporation Information
12.6.2 Millennium Pharmaceuticals Inc Business Overview
12.6.3 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Products Offered
12.6.5 Millennium Pharmaceuticals Inc Recent Development
12.7 MolMed S.p.A.
12.7.1 MolMed S.p.A. Corporation Information
12.7.2 MolMed S.p.A. Business Overview
12.7.3 MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2016-2021)
12.7.4 MolMed S.p.A. Metastatic Ovarian Cancer Drug Products Offered
12.7.5 MolMed S.p.A. Recent Development
12.8 Natco Pharma Limited
12.8.1 Natco Pharma Limited Corporation Information
12.8.2 Natco Pharma Limited Business Overview
12.8.3 Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Natco Pharma Limited Metastatic Ovarian Cancer Drug Products Offered
12.8.5 Natco Pharma Limited Recent Development
12.9 Northwest Biotherapeutics, Inc.
12.9.1 Northwest Biotherapeutics, Inc. Corporation Information
12.9.2 Northwest Biotherapeutics, Inc. Business Overview
12.9.3 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Products Offered
12.9.5 Northwest Biotherapeutics, Inc. Recent Development
12.10 Pfizer Inc.
12.10.1 Pfizer Inc. Corporation Information
12.10.2 Pfizer Inc. Business Overview
12.10.3 Pfizer Inc. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Pfizer Inc. Metastatic Ovarian Cancer Drug Products Offered
12.10.5 Pfizer Inc. Recent Development
12.11 Richter Gedeon Nyrt.
12.11.1 Richter Gedeon Nyrt. Corporation Information
12.11.2 Richter Gedeon Nyrt. Business Overview
12.11.3 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Products Offered
12.11.5 Richter Gedeon Nyrt. Recent Development
12.12 Sumitomo Dainippon Pharma Co., Ltd.
12.12.1 Sumitomo Dainippon Pharma Co., Ltd. Corporation Information
12.12.2 Sumitomo Dainippon Pharma Co., Ltd. Business Overview
12.12.3 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Products Offered
12.12.5 Sumitomo Dainippon Pharma Co., Ltd. Recent Development
12.13 VG Life Sciences, Inc.
12.13.1 VG Life Sciences, Inc. Corporation Information
12.13.2 VG Life Sciences, Inc. Business Overview
12.13.3 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales, Revenue and Gross Margin (2016-2021)
12.13.4 VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Products Offered
12.13.5 VG Life Sciences, Inc. Recent Development

13 Metastatic Ovarian Cancer Drug Manufacturing Cost Analysis
13.1 Metastatic Ovarian Cancer Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Metastatic Ovarian Cancer Drug
13.4 Metastatic Ovarian Cancer Drug Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Metastatic Ovarian Cancer Drug Distributors List
14.3 Metastatic Ovarian Cancer Drug Customers

15 Market Dynamics
15.1 Metastatic Ovarian Cancer Drug Market Trends
15.2 Metastatic Ovarian Cancer Drug Drivers
15.3 Metastatic Ovarian Cancer Drug Market Challenges
15.4 Metastatic Ovarian Cancer Drug Market Restraints

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Metastatic Ovarian Cancer Drug Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global Metastatic Ovarian Cancer Drug Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global Metastatic Ovarian Cancer Drug Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global Metastatic Ovarian Cancer Drug Sales (K Pcs) by Region (2016-2021)
Table 5. Global Metastatic Ovarian Cancer Drug Sales Market Share by Region (2016-2021)
Table 6. Global Metastatic Ovarian Cancer Drug Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global Metastatic Ovarian Cancer Drug Revenue Share by Region (2016-2021)
Table 8. Global Metastatic Ovarian Cancer Drug Sales (K Pcs) Forecast by Region (2022-2027)
Table 9. Global Metastatic Ovarian Cancer Drug Sales Market Share Forecast by Region (2022-2027)
Table 10. Global Metastatic Ovarian Cancer Drug Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global Metastatic Ovarian Cancer Drug Revenue Share Forecast by Region (2022-2027)
Table 12. Global Metastatic Ovarian Cancer Drug Sales (K Pcs) of Key Companies (2016-2021)
Table 13. Global Metastatic Ovarian Cancer Drug Sales Share by Company (2016-2021)
Table 14. Global Metastatic Ovarian Cancer Drug Revenue (US$ Million) by Company (2016-2021)
Table 15. Global Metastatic Ovarian Cancer Drug Revenue Share by Company (2016-2021)
Table 16. Global Metastatic Ovarian Cancer Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metastatic Ovarian Cancer Drug as of 2020)
Table 17. Global Metastatic Ovarian Cancer Drug Average Price (USD/Pcs) of Key Company (2016-2021)
Table 18. Manufacturers Metastatic Ovarian Cancer Drug Manufacturing Sites and Area Served
Table 19. Manufacturers Metastatic Ovarian Cancer Drug Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global Metastatic Ovarian Cancer Drug Sales (K Pcs) by Type (2016-2021)
Table 22. Global Metastatic Ovarian Cancer Drug Sales Share by Type (2016-2021)
Table 23. Global Metastatic Ovarian Cancer Drug Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global Metastatic Ovarian Cancer Drug Price (USD/Pcs) by Type (2016-2021)
Table 25. Global Metastatic Ovarian Cancer Drug Sales Share by Type (2022-2027)
Table 26. Global Metastatic Ovarian Cancer Drug Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global Metastatic Ovarian Cancer Drug Revenue Share by Type (2022-2027)
Table 28. Global Metastatic Ovarian Cancer Drug Price (USD/Pcs) by Type (2022-2027)
Table 29. Global Metastatic Ovarian Cancer Drug Sales (K Pcs) by Application (2016-2021)
Table 30. Global Metastatic Ovarian Cancer Drug Sales Share by Application (2016-2021)
Table 31. Global Metastatic Ovarian Cancer Drug Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global Metastatic Ovarian Cancer Drug Price (USD/Pcs) by Application (2016-2021)
Table 33. Global Metastatic Ovarian Cancer Drug Sales (K Pcs) by Application (2022-2027)
Table 34. Global Metastatic Ovarian Cancer Drug Sales Share by Application (2022-2027)
Table 35. Global Metastatic Ovarian Cancer Drug Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global Metastatic Ovarian Cancer Drug Revenue Share by Application (2022-2027)
Table 37. Global Metastatic Ovarian Cancer Drug Price (USD/Pcs) by Application (2022-2027)
Table 38. North America Metastatic Ovarian Cancer Drug Sales (K Pcs) by Company (2016-2021)
Table 39. North America Metastatic Ovarian Cancer Drug Sales Market Share by Company (2016-2021)
Table 40. North America Metastatic Ovarian Cancer Drug Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America Metastatic Ovarian Cancer Drug Revenue Market Share by Company (2016-2021)
Table 42. North America Metastatic Ovarian Cancer Drug Sales by Type (2016-2021) & (K Pcs)
Table 43. North America Metastatic Ovarian Cancer Drug Sales Market Share by Type (2016-2021)
Table 44. North America Metastatic Ovarian Cancer Drug Sales by Type (2022-2027) & (K Pcs)
Table 45. North America Metastatic Ovarian Cancer Drug Sales Market Share by Type (2022-2027)
Table 46. North America Metastatic Ovarian Cancer Drug Sales by Application (2016-2021) & (K Pcs)
Table 47. North America Metastatic Ovarian Cancer Drug Sales Market Share by Application (2016-2021)
Table 48. North America Metastatic Ovarian Cancer Drug Sales by Application (2022-2027) & (K Pcs)
Table 49. North America Metastatic Ovarian Cancer Drug Sales Market Share by Application (2022-2027)
Table 50. Europe Metastatic Ovarian Cancer Drug Sales (K Pcs) by Company (2016-2021)
Table 51. Europe Metastatic Ovarian Cancer Drug Sales Market Share by Company (2016-2021)
Table 52. Europe Metastatic Ovarian Cancer Drug Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe Metastatic Ovarian Cancer Drug Revenue Market Share by Company (2016-2021)
Table 54. Europe Metastatic Ovarian Cancer Drug Sales by Type (2016-2021) & (K Pcs)
Table 55. Europe Metastatic Ovarian Cancer Drug Sales Market Share by Type (2016-2021)
Table 56. Europe Metastatic Ovarian Cancer Drug Sales by Type (2022-2027) & (K Pcs)
Table 57. Europe Metastatic Ovarian Cancer Drug Sales Market Share by Type (2022-2027)
Table 58. Europe Metastatic Ovarian Cancer Drug Sales by Application (2016-2021) & (K Pcs)
Table 59. Europe Metastatic Ovarian Cancer Drug Sales Market Share by Application (2016-2021)
Table 60. Europe Metastatic Ovarian Cancer Drug Sales by Application (2022-2027) & (K Pcs)
Table 61. Europe Metastatic Ovarian Cancer Drug Sales Market Share by Application (2022-2027)
Table 62. China Metastatic Ovarian Cancer Drug Sales (K Pcs) by Company (2016-2021)
Table 63. China Metastatic Ovarian Cancer Drug Sales Market Share by Company (2016-2021)
Table 64. China Metastatic Ovarian Cancer Drug Revenue by Company (2016-2021) & (US$ Million)
Table 65. China Metastatic Ovarian Cancer Drug Revenue Market Share by Company (2016-2021)
Table 66. China Metastatic Ovarian Cancer Drug Sales by Type (2016-2021) & (K Pcs)
Table 67. China Metastatic Ovarian Cancer Drug Sales Market Share by Type (2016-2021)
Table 68. China Metastatic Ovarian Cancer Drug Sales by Type (2022-2027) & (K Pcs)
Table 69. China Metastatic Ovarian Cancer Drug Sales Market Share by Type (2022-2027)
Table 70. China Metastatic Ovarian Cancer Drug Sales by Application (2016-2021) & (K Pcs)
Table 71. China Metastatic Ovarian Cancer Drug Sales Market Share by Application (2016-2021)
Table 72. China Metastatic Ovarian Cancer Drug Sales by Application (2022-2027) & (K Pcs)
Table 73. China Metastatic Ovarian Cancer Drug Sales Market Share by Application (2022-2027)
Table 74. Japan Metastatic Ovarian Cancer Drug Sales (K Pcs) by Company (2016-2021)
Table 75. Japan Metastatic Ovarian Cancer Drug Sales Market Share by Company (2016-2021)
Table 76. Japan Metastatic Ovarian Cancer Drug Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan Metastatic Ovarian Cancer Drug Revenue Market Share by Company (2016-2021)
Table 78. Japan Metastatic Ovarian Cancer Drug Sales by Type (2016-2021) & (K Pcs)
Table 79. Japan Metastatic Ovarian Cancer Drug Sales Market Share by Type (2016-2021)
Table 80. Japan Metastatic Ovarian Cancer Drug Sales by Type (2022-2027) & (K Pcs)
Table 81. Japan Metastatic Ovarian Cancer Drug Sales Market Share by Type (2022-2027)
Table 82. Japan Metastatic Ovarian Cancer Drug Sales by Application (2016-2021) & (K Pcs)
Table 83. Japan Metastatic Ovarian Cancer Drug Sales Market Share by Application (2016-2021)
Table 84. Japan Metastatic Ovarian Cancer Drug Sales by Application (2022-2027) & (K Pcs)
Table 85. Japan Metastatic Ovarian Cancer Drug Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia Metastatic Ovarian Cancer Drug Sales (K Pcs) by Company (2016-2021)
Table 87. Southeast Asia Metastatic Ovarian Cancer Drug Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia Metastatic Ovarian Cancer Drug Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia Metastatic Ovarian Cancer Drug Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia Metastatic Ovarian Cancer Drug Sales by Type (2016-2021) & (K Pcs)
Table 91. Southeast Asia Metastatic Ovarian Cancer Drug Sales Market Share by Type (2016-2021)
Table 92. Southeast Asia Metastatic Ovarian Cancer Drug Sales by Type (2022-2027) & (K Pcs)
Table 93. Southeast Asia Metastatic Ovarian Cancer Drug Sales Market Share by Type (2022-2027)
Table 94. Southeast Asia Metastatic Ovarian Cancer Drug Sales by Application (2016-2021) & (K Pcs)
Table 95. Southeast Asia Metastatic Ovarian Cancer Drug Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia Metastatic Ovarian Cancer Drug Sales by Application (2022-2027) & (K Pcs)
Table 97. Southeast Asia Metastatic Ovarian Cancer Drug Sales Market Share by Application (2022-2027)
Table 98. India Metastatic Ovarian Cancer Drug Sales (K Pcs) by Company (2016-2021)
Table 99. India Metastatic Ovarian Cancer Drug Sales Market Share by Company (2016-2021)
Table 100. India Metastatic Ovarian Cancer Drug Revenue by Company (2016-2021) & (US$ Million)
Table 101. India Metastatic Ovarian Cancer Drug Revenue Market Share by Company (2016-2021)
Table 102. India Metastatic Ovarian Cancer Drug Sales by Type (2016-2021) & (K Pcs)
Table 103. India Metastatic Ovarian Cancer Drug Sales Market Share by Type (2016-2021)
Table 104. India Metastatic Ovarian Cancer Drug Sales by Type (2022-2027) & (K Pcs)
Table 105. India Metastatic Ovarian Cancer Drug Sales Market Share by Type (2022-2027)
Table 106. India Metastatic Ovarian Cancer Drug Sales by Application (2016-2021) & (K Pcs)
Table 107. India Metastatic Ovarian Cancer Drug Sales Market Share by Application (2016-2021)
Table 108. India Metastatic Ovarian Cancer Drug Sales by Application (2022-2027) & (K Pcs)
Table 109. India Metastatic Ovarian Cancer Drug Sales Market Share by Application (2022-2027)
Table 110. Adgero Biopharmaceuticals Inc Corporation Information
Table 111. Adgero Biopharmaceuticals Inc Description and Business Overview
Table 112. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 113. Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Product
Table 114. Adgero Biopharmaceuticals Inc Recent Development
Table 115. Cellceutix Corporation Corporation Information
Table 116. Cellceutix Corporation Description and Business Overview
Table 117. Cellceutix Corporation Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 118. Cellceutix Corporation Metastatic Ovarian Cancer Drug Product
Table 119. Cellceutix Corporation Recent Development
Table 120. Eisai Co., Ltd. Corporation Information
Table 121. Eisai Co., Ltd. Description and Business Overview
Table 122. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 123. Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Product
Table 124. Eisai Co., Ltd. Recent Development
Table 125. F. Hoffmann-La Roche Ltd. Corporation Information
Table 126. F. Hoffmann-La Roche Ltd. Description and Business Overview
Table 127. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 128. F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Product
Table 129. F. Hoffmann-La Roche Ltd. Recent Development
Table 130. Immune Design Corp. Corporation Information
Table 131. Immune Design Corp. Description and Business Overview
Table 132. Immune Design Corp. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 133. Immune Design Corp. Metastatic Ovarian Cancer Drug Product
Table 134. Immune Design Corp. Recent Development
Table 135. Millennium Pharmaceuticals Inc Corporation Information
Table 136. Millennium Pharmaceuticals Inc Description and Business Overview
Table 137. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 138. Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Product
Table 139. Millennium Pharmaceuticals Inc Recent Development
Table 140. MolMed S.p.A. Corporation Information
Table 141. MolMed S.p.A. Description and Business Overview
Table 142. MolMed S.p.A. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 143. MolMed S.p.A. Metastatic Ovarian Cancer Drug Product
Table 144. MolMed S.p.A. Recent Development
Table 145. Natco Pharma Limited Corporation Information
Table 146. Natco Pharma Limited Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 147. Natco Pharma Limited Description and Business Overview
Table 148. Natco Pharma Limited Metastatic Ovarian Cancer Drug Product
Table 149. Natco Pharma Limited Recent Development
Table 150. Northwest Biotherapeutics, Inc. Corporation Information
Table 151. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 152. Northwest Biotherapeutics, Inc. Description and Business Overview
Table 153. Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Product
Table 154. Northwest Biotherapeutics, Inc. Recent Development
Table 155. Pfizer Inc. Corporation Information
Table 156. Pfizer Inc. Description and Business Overview
Table 157. Pfizer Inc. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 158. Pfizer Inc. Metastatic Ovarian Cancer Drug Product
Table 159. Pfizer Inc. Recent Development
Table 160. Richter Gedeon Nyrt. Corporation Information
Table 161. Richter Gedeon Nyrt. Description and Business Overview
Table 162. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 163. Richter Gedeon Nyrt. Metastatic Ovarian Cancer Drug Product
Table 164. Richter Gedeon Nyrt. Recent Development
Table 165. Sumitomo Dainippon Pharma Co., Ltd. Corporation Information
Table 166. Sumitomo Dainippon Pharma Co., Ltd. Description and Business Overview
Table 167. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 168. Sumitomo Dainippon Pharma Co., Ltd. Metastatic Ovarian Cancer Drug Product
Table 169. Sumitomo Dainippon Pharma Co., Ltd. Recent Development
Table 170. VG Life Sciences, Inc. Corporation Information
Table 171. VG Life Sciences, Inc. Description and Business Overview
Table 172. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 173. VG Life Sciences, Inc. Metastatic Ovarian Cancer Drug Product
Table 174. VG Life Sciences, Inc. Recent Development
Table 175. Production Base and Market Concentration Rate of Raw Material
Table 176. Key Suppliers of Raw Materials
Table 177. Metastatic Ovarian Cancer Drug Distributors List
Table 178. Metastatic Ovarian Cancer Drug Customers List
Table 179. Metastatic Ovarian Cancer Drug Market Trends
Table 180. Metastatic Ovarian Cancer Drug Market Drivers
Table 181. Metastatic Ovarian Cancer Drug Market Challenges
Table 182. Metastatic Ovarian Cancer Drug Market Restraints
Table 183. Research Programs/Design for This Report
Table 184. Key Data Information from Secondary Sources
Table 185. Key Data Information from Primary Sources
List of Figures
Figure 1. Metastatic Ovarian Cancer Drug Product Picture
Figure 2. Global Metastatic Ovarian Cancer Drug Sales Market Share by Type in 2021 & 2027
Figure 3. E-7449 Product Picture
Figure 4. Crizotinib Product Picture
Figure 5. CMB-305 Product Picture
Figure 6. G-305 Product Picture
Figure 7. LV-305 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Metastatic Ovarian Cancer Drug Sales Market Share by Application in 2021 & 2027
Figure 10. Clinic Examples
Figure 11. Hospital Examples
Figure 12. Others Examples
Figure 13. Global Metastatic Ovarian Cancer Drug Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Metastatic Ovarian Cancer Drug Sales Growth Rate (2016-2027) & (US$ Million)
Figure 15. Global Metastatic Ovarian Cancer Drug Sales (K Pcs) Growth Rate (2016-2027)
Figure 16. Global Metastatic Ovarian Cancer Drug Price Trends Growth Rate (2016-2027) (USD/Pcs)
Figure 17. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Region: 2016 VS 2021
Figure 18. Global Metastatic Ovarian Cancer Drug Revenue Market Share by Region: 2021 VS 2027
Figure 19. North America Metastatic Ovarian Cancer Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 20. North America Metastatic Ovarian Cancer Drug Sales (K Pcs) Growth Rate (2016-2027)
Figure 21. Europe Metastatic Ovarian Cancer Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 22. Europe Metastatic Ovarian Cancer Drug Sales (Million USD) Growth Rate (2016-2027)
Figure 23. China Metastatic Ovarian Cancer Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 24. China Metastatic Ovarian Cancer Drug Sales (Million USD) and Growth Rate (2016-2027)
Figure 25. Japan Metastatic Ovarian Cancer Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 26. Japan Metastatic Ovarian Cancer Drug Sales (Million USD) Growth Rate (2016-2027)
Figure 27. Southeast Asia Metastatic Ovarian Cancer Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 28. Southeast Asia Metastatic Ovarian Cancer Drug Sales (Million USD) Growth Rate (2016-2027)
Figure 29. India Metastatic Ovarian Cancer Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 30. India Metastatic Ovarian Cancer Drug Sales (Million USD) Growth Rate (2016-2027)
Figure 31. Global 5 Largest Metastatic Ovarian Cancer Drug Players Market Share by Revenue in Metastatic Ovarian Cancer Drug: 2016 & 2020
Figure 32. Metastatic Ovarian Cancer Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 33. Global Metastatic Ovarian Cancer Drug Revenue Share by Type (2016-2021)
Figure 34. Global Metastatic Ovarian Cancer Drug Revenue Growth Rate by Type in 2016 & 2020
Figure 35. Global Metastatic Ovarian Cancer Drug Revenue Share by Application (2016-2021)
Figure 36. Global Metastatic Ovarian Cancer Drug Revenue Growth Rate by Application in 2016 & 2020
Figure 37. North America Metastatic Ovarian Cancer Drug Sales Market Share by Type in 2020
Figure 38. North America Metastatic Ovarian Cancer Drug Sales Market Share by Application in 2020
Figure 39. Europe Metastatic Ovarian Cancer Drug Sales Market Share by Type in 2020
Figure 40. Europe Metastatic Ovarian Cancer Drug Sales Market Share by Application in 2020
Figure 41. China Metastatic Ovarian Cancer Drug Sales Market Share by Type in 2020
Figure 42. China Metastatic Ovarian Cancer Drug Sales Market Share by Application in 2020
Figure 43. Japan Metastatic Ovarian Cancer Drug Sales Market Share by Type in 2020
Figure 44. Japan Metastatic Ovarian Cancer Drug Sales Market Share by Application in 2020
Figure 45. Southeast Asia Metastatic Ovarian Cancer Drug Sales Market Share by Type in 2020
Figure 46. Southeast Asia Metastatic Ovarian Cancer Drug Sales Market Share by Application in 2020
Figure 47. India Metastatic Ovarian Cancer Drug Sales Market Share by Type in 2020
Figure 48. India Metastatic Ovarian Cancer Drug Sales Market Share by Application in 2020
Figure 49. Key Raw Materials Price Trend
Figure 50. Manufacturing Cost Structure of Metastatic Ovarian Cancer Drug
Figure 51. Manufacturing Process Analysis of Metastatic Ovarian Cancer Drug
Figure 52. Metastatic Ovarian Cancer Drug Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed